These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 11890362)

  • 21. [A randomized crossover comparison of azasetron and granisetron in the prophylaxis of emesis induced by chemotherapy including cisplatin].
    Tsukuda M; Mochimatsu I; Furukawa M; Kohno H; Kawai S; Enomoto H; Yago T; Matsuda H; Ikema Y; Zhou L
    Gan To Kagaku Ryoho; 1995 Nov; 22(13):1959-67. PubMed ID: 7487127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contemporary thoughts on the treatment of irritable bowel syndrome.
    Giaquinta D
    Manag Care Interface; 2002 Aug; 15(8):19-20, 22. PubMed ID: 12229060
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of oral itasetron with oral ondansetron: results of a double-blind, active-controlled phase II study in chemotherapy-naive patients receiving moderately emetogenic chemotherapy.
    Goldschmidt H; Salwender H; Egerer G; Kempe R; Voigt T
    Anticancer Drugs; 1997 Jun; 8(5):436-44. PubMed ID: 9215605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome.
    Zakko S; Barton G; Weber E; Dunger-Baldauf C; Rühl A
    Aliment Pharmacol Ther; 2011 Jun; 33(12):1311-21. PubMed ID: 21507028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renzapride in IBS: is efficacy in the eye of the beholder?
    Ford AC
    Aliment Pharmacol Ther; 2010 Jul; 32(1):113-4; author reply 114-5. PubMed ID: 20597877
    [No Abstract]   [Full Text] [Related]  

  • 26. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects.
    Morganroth J; Rüegg PC; Dunger-Baldauf C; Appel-Dingemanse S; Bliesath H; Lefkowitz M
    Am J Gastroenterol; 2002 Sep; 97(9):2321-7. PubMed ID: 12358251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Irritable colon].
    Meier R; Meyer M; Degen L
    Ther Umsch; 1997 Nov; 54(11):654-60. PubMed ID: 9454369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Irritable bowel syndrome: new approaches to its pharmacological management.
    Tougas G
    Can J Gastroenterol; 2001 Oct; 15 Suppl B():12B-13B. PubMed ID: 11694909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The use of Debridat in treating the irritable bowel syndrome].
    Parfenov AI
    Voen Med Zh; 1996 May; 317(5):37-8. PubMed ID: 8754091
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms.
    Fidelholtz J; Smith W; Rawls J; Shi Y; Zack A; Rüegg P; Lefkowitz M
    Am J Gastroenterol; 2002 May; 97(5):1176-81. PubMed ID: 12014724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological treatment of the irritable bowel syndrome and other functional bowel disorders.
    Mearin F
    Digestion; 2006; 73 Suppl 1():28-37. PubMed ID: 16498250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alicaforsen. Isis Pharmaceuticals.
    Gewirtz AT; Sitaraman S
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1401-6. PubMed ID: 11890355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on irritable bowel syndrome.
    Bergmann KA
    Postgrad Med J; 2003 Dec; 79(938):715. PubMed ID: 14707260
    [No Abstract]   [Full Text] [Related]  

  • 34. Lotronex(tm): therapy for diarrhea predominant irritable bowel syndrome.
    McGahan L
    Issues Emerg Health Technol; 2000 Oct; (11):1-5. PubMed ID: 11902219
    [No Abstract]   [Full Text] [Related]  

  • 35. Safinamide (Newron Pharmaceuticals).
    Chazot PL
    Curr Opin Investig Drugs; 2001 Jun; 2(6):809-13. PubMed ID: 11572661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
    Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
    Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA OK's two drugs for irritable bowel syndrome. The arsenal of IBS drugs is growing, but diagnosis is tricky.
    Horwitz BJ
    Health News; 2002 Oct; 8(10):1-2. PubMed ID: 12416480
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting.
    George AM; Meyers NL; Hickling RI
    Aliment Pharmacol Ther; 2008 May; 27(9):830-7. PubMed ID: 18284648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cilansetron. Solvay.
    Stacher G
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1432-6. PubMed ID: 11890360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Meteospazmil and its place in treating patients with irritable bowel syndrome].
    Minushkin ON
    Eksp Klin Gastroenterol; 2002; (1):94-7. PubMed ID: 12271597
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.